Immunohistochemical analyses reveal that stromal expression of CD68 and CD163 positively correlates with VEGF-A/C levels, and the abundance of CD163+/CD68+ TAMs is significantly associated with poor prognosis in NSCLC patients (37, 48). This evidence concerns the gene VEGFA and non-small cell lung carcinoma.